Tseng, William W.
Swallow, Carol J.
Strauss, Dirk C.
Bonvalot, Sylvie
Rutkowski, Piotr
Ford, Samuel J.
Gonzalez, Ricardo J.
Gladdy, Rebecca A.
Gyorki, David E.
Fairweather, Mark
Lee, Kyo Won
Albertsmeier, Markus
van Houdt, Winan J.
Fau, Magalie
Nessim, Carolyn
Grignani, Giovanni
Cardona, Kenneth
Quagliuolo, Vittorio
Grignol, Valerie
Farma, Jeffrey M.
Pennacchioli, Elisabetta
Fiore, Marco
Hayes, Andrew
Tzanis, Dimitri
Skoczylas, Jacek
Almond, Max L.
Mullinax, John E.
Johnston, Wendy
Snow, Hayden
Haas, Rick L.
Callegaro, Dario
Smith, Myles J.
Bouhadiba, Toufik
Desai, Anant
Voss, Rachel
Sanfilippo, Roberta
Jones, Robin L.
Baldini, Elizabeth H.
Wagner, Andrew J.
Catton, Charles N.
Stacchiotti, Silvia
Thway, Khin
Roland, Christina L.
Raut, Chandrajit P.
Gronchi, Alessandro
,
Article History
Received: 12 February 2022
Accepted: 20 April 2022
First Online: 29 June 2022
Disclosure
: These authors disclose the following financial relationships: Piotr Rutkowski: honoraria for lectures and Advisory Boards from BMS, MSD, Novartis, Pierre Fabre, Sanofi, Merck, Blueprint Medicines and Philogen outside of the scope of this article; David Gyorki: Speaker bureau – BMS, Novartis, Advisory Board – Amgen, Bayer, Q Biotics. Provectus; Silvia Stacchiotti: Institutional research funding from Amgen Dompe, Advenchen, Bayer, Blueprint Medicines, Deciphera, Eli Lilly, Epizyme, Daiichi Sankyo Pharma, GSK, Karyopharm, Novartis, Pfizer, PharmaMar, SpringWorks, and Hutchinson MediPharma International Inc; honoraria from Aadi, Bayer, Deciphera, Daiichi, Novartis, Pharmamar; fees for expert testimony from Bavarian Nordic and Epizyme; and participation on Advisory Board for Bayer, Deciphera, Eli Lilly, Daiichi, Ikena, Maxivax, Novartis, Rain Therapeutics, Pharmamar outside the submitted work. Christina Roland: Research Funds – Bristol Myers Squibb. All other authors have nothing to report.